Progress and application of circulating tumor cells in non-small cell lung cancer

Qian, Haoliang; Zhang, Yue; Xu, Jing; He, Jing; Gao, Wen

doi:10.1016/j.omto.2021.05.005

Cited by 23 publications

(15 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Larger CTC clusters result in more metastases than smaller clusters. CTC clusters undergo epidermal-mesenchymal-transition (EMT) through the secretion of TGF-β by platelets who have also aggregated within the cluster [52]. CTC detection in early-stage NSCLC is negatively correlated to overall and disease-free survival, whereas CTC detection in advanced NSCLC is related to worsening prognosis [53].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Molecular Markers in Guiding Lung Cancer Diagnosis and Treatment

Li¹,

Vigneswaran²

2022

JOMH

View full text Add to dashboard Cite

Background: Lung cancer has the highest mortality rates and one of the lowest 5-year survival rates amongst cancer types in the world. Although there are constant advancements in treatment, the overall prognosis for lung cancer continues to be poor. In order to achieve early detection and personalized targeted treatment, an effective method is needed to make prognostic and treatment decisions. Methods: A thorough literature search was conducted to identify tumor tissue, blood, and expired breath markers that have been discovered in lung cancer. Articles were chosen by determining main markers holding promise for future clinical use. Results: Data suggests significance in using tumor tissue markers as promising diagnostic, prognostic and predictive of treatment response and outcome. Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) and ROS-1 biomarkers can be used to decide to treat with EGFR-TKI and ALK-TKI, respectively. KRAS and p53 mutations suggest a likelihood of developing EGFR-TKI resistance. And c-MET is showing pertinence in predicting disease recurrence. Blood and expired breath markers are two more novel sources for biomarkers that is gaining more ground in lung cancer research. Circulating tumor cells (CTC) and DNA (ctDNA) were shown to be important markers in lung cancer prognosis and treatment response prediction. Circulating tumor cells suggest negative prognosis and increased likelihood of recurrence, while ctDNA data indicates use in treatment monitoring to help make decisions without keeping patients on disagreeable therapies. Volatile organic compounds (VOC) are the least studied, but investigators have noticed changes in VOC profiles between healthy and lung cancer patients. Blood and expired breath markers continue to be studied as these would be a welcome alternative to invasive biopsies. Recently there had been interest in using specific tumor biomarkers for imaging to localize tumors and determine disease progression. Conclusions: Years of research have elucidated multiple candidates as biomarkers found in tumor tissues, circulation, and even in exhaled air. Although more studies need to be performed on some markers mentioned in this review, such as EGFR, KRAS, ALK, and ROS-1, there is enough evidence for some use of these biomarkers to guide decisions in clinic, as well as evidence for promising future developments.

show abstract

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Molecular Markers in Guiding Lung Cancer Diagnosis and Treatment

Li¹,

Vigneswaran²

2022

JOMH

View full text Add to dashboard Cite

show abstract

“…It was found that the overall survival and progression free survival of patients with high levels of ctDNA were significantly shorter than those with low levels of ctDNA. ctDNA above baseline indicated a poor prognosis [ 30 ], and it may be more reliable if combined with the dynamic changes of ctDNA [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

et al. 2022

View full text Add to dashboard Cite

Primary lung cancer is one of the most common malignant tumors in China. Approximately 60% of lung cancer patients have distant metastasis at the initial diagnosis, so it is necessary to find new tumor markers for early diagnosis and individualized treatment. Tumor markers contribute to the early diagnosis of lung cancer and play important roles in early detection and treatment, as well as in precision medicine, efficacy monitoring, and prognosis prediction. The pathological diagnosis of lung cancer in small biopsy specimens determines whether there are tumor cells in the biopsy and tumor type. Because biopsy is traumatic and the compliance of patients with multiple biopsies is poor, liquid biopsy has become a hot research direction. Liquid biopsies are advantageous because they are nontraumatic, easy to obtain, reflect the overall state of the tumor, and allow for real-time monitoring. At present, liquid biopsies mainly include circulating tumor cells, circulating tumor DNA, exosomes, microRNA, circulating RNA, tumor platelets, and tumor endothelial cells. This review introduces the research progress and clinical application prospect of liquid biopsy technology for lung cancer.

show abstract

“…The reason for the high mortality rate of NSCLC is that patients were diagnosed at an advanced stage or local late-stage, missing the possibility of early cure. The leading causes include lack of routine physical examination, lack of biomarkers for early diagnosis, and disease surveillance methods ( Qian et al, 2021 ). Therefore, with the progress of imaging, more sensitive and specific tumor biomarkers are needed to screen and diagnose NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Assessment of Serum hsa_circ_0070354 as a Novel Diagnostic and Predictive Biomarker in Non-small Cell Lung Cancer

Huang

Qin

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: More and more studies have shown that circular RNAs (circRNAs) play an essential role in the occurrence and development of tumors. Hence, they can be used as biomarkers to assist in diagnosing tumors. This study focuses on exploring the role of circular RNA (hsa_circ_0070354) in the diagnosis and prognosis of non-small cell lung cancer (NSCLC).Materials and Methods: First of all, high-throughput sequencing was used to find the difference in the expression of circular RNA between NSCLC and adjacent tissues. The circRNAs with higher differences in expression were selected to verify their expressions in tissues, cells, and serum using qRT-PCR. Secondly, the hsa_circ_0070354 with a significant difference was chosen as the research goal, and the molecular properties were verified by agarose gel electrophoresis and Sanger sequencing, etc. Then, actinomycin D and repeated freeze-thaw were used to explore the stability and repeatability of hsa_circ_0070354. Finally, the expression of hsa_circ_0070354 in serum of 133 patients with NSCLC and 97 normal donors was detected, and its sensitivity, specificity, and prognosis as tumor markers were statistically analyzed.Results: Hsa_circ_0070354 was highly expressed in tissues, cells, and serum of NSCLC, and it has the characteristics of sensitivity, stability, and repeatability. The ROC curve indicates that hsa_circ_0070354 is superior to conventional tumor markers in detecting NSCLC, and the combined diagnosis is of more significance in the diagnosis. The high expression of hsa_circ_0070354 is closely related to the late-stage, poor differentiation of the tumor and the short survival time of the patients, which is an independent indicator of poor prognosis.Conclusion: Hsa_circ_0070354 is not only a novel sensitive index for the diagnosis of NSCLC but also a crucial marker for bad biological behavior.

show abstract

Progress and application of circulating tumor cells in non-small cell lung cancer

Cited by 23 publications

References 121 publications

Molecular Markers in Guiding Lung Cancer Diagnosis and Treatment

Molecular Markers in Guiding Lung Cancer Diagnosis and Treatment

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

Comprehensive Assessment of Serum hsa_circ_0070354 as a Novel Diagnostic and Predictive Biomarker in Non-small Cell Lung Cancer

Contact Info

Product

Resources

About